San Diego, CA – February 21st, 20011 -
Avineuro Pharmaceuticals, Inc. reported today positive top-line results from a Phase 2a clinical proof of concept trial to assess AVN-211 as an augmentation therapy to improve cognition in schizophrenia patients. In a double blind trial in 50 patients stabilized on an atypical antipsychotic therapy, AVN-211 met the protocol [...]

San Diego, CA – March 1st, 2010 – Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-322, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Alzheimer’s disease. AVN-322 was well tolerated in a wide range of doses and no adverse events were observed. Avineuro Pharmaceuticals, Inc. plans to [...]

Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase II clinical studies of AVN-101, a potent multi-target small molecule for treatment of Alzheimer’s disease and anxiety.

Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-101, a potent small molecule for treatment of Alzheimer’s disease.

ChemDiv Inc. of San Diego CA and Avineuro Pharmaceuticals Inc. of San Diego CA announced successful milestones reached under ongoing research and development collaboration in area of neurodegenerative and psychiatric disorders.